Botulinum Toxin in Secondarily Nonresponsive Patients with Spasmodic Dysphonia

Area of Science:

• Neurology
• Pharmacology

Background:

• Chemodenervation using botulinum toxin (BoNT) is a long-established treatment for dystonia.
• Secondary nonresponse to BoNT can occur in patients with various dystonia types.

Purpose of the Study:

• To investigate the incidence and characteristics of secondary nonresponse to botulinum toxin type A (BoNT-A) in patients with spasmodic dysphonia (SD).
• To assess the possibility of resuming BoNT-A treatment after a period of nonresponse.

Main Methods:

• Retrospective review of patients with SD treated with BoNT-A.
• Analysis of secondary nonresponse rates and outcomes after treatment cessation and reinitiation.

Main Results:

• A low rate of secondary nonresponse to BoNT-A (0.57%) was observed in SD patients, lower than in other dystonias.
• Four out of four patients who resumed BoNT-A after cessation did not experience recurrence of immunoresistance.
• SD patients typically receive significantly lower doses of BoNT-A compared to other dystonias.

Conclusions:

• The low incidence of secondary nonresponse in SD may be attributed to the extremely low doses of BoNT-A used.
• Small antigen exposure could contribute to reduced immunoresistance and sustained efficacy upon reinitiation of BoNT-A in SD patients.